Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Debt (2017 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Non-Current Debt for 9 consecutive years, with $291.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 5.59% to $291.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $291.8 million through Dec 2025, down 5.59% year-over-year, with the annual reading at $291.8 million for FY2025, 5.59% down from the prior year.
  • Non-Current Debt hit $291.8 million in Q4 2025 for Ani Pharmaceuticals, down from $297.7 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $312.9 million in Q3 2024 to a low of $169.0 million in Q1 2021.
  • Historically, Non-Current Debt has averaged $275.1 million across 5 years, with a median of $285.8 million in 2022.
  • Biggest five-year swings in Non-Current Debt: decreased 10.16% in 2021 and later surged 69.43% in 2022.
  • Year by year, Non-Current Debt stood at $286.5 million in 2021, then decreased by 0.3% to $285.7 million in 2022, then decreased by 0.3% to $284.8 million in 2023, then grew by 8.53% to $309.1 million in 2024, then fell by 5.59% to $291.8 million in 2025.
  • Business Quant data shows Non-Current Debt for ANIP at $291.8 million in Q4 2025, $297.7 million in Q3 2025, and $301.5 million in Q2 2025.